All lobbying filings

Splitoak Strategies LLC

Splitoak Strategies LLC filed a Q3 report for Johnson & Johnson Services, Inc. on October 20, 2026, reporting $50,000 in lobbying income.

Lobbying for Johnson & Johnson Services, Inc. · Global biopharmaceutical, medical device and consumer product manufacturer.

As filed: SPLITOAK STRATEGIES LLC for JOHNSON & JOHNSON SERVICES, INC.

All filings by Splitoak Strategies LLC · Everything Johnson & Johnson Services, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 3

SARAH KUEHL EGGE

Previously held: Sarah: 1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Democratic Staff of the Senate Budget Committee (Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee for Deficit Reduction
AMY JENSEN

Previously held: Amy: 1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Special Affairs
ARIELLE WORONOFF New on this filing

Previously held: Arielle: Counsel, Rep. Sandy Levin (10/2012-3/2014); Leg. Asst, Sen. Booker, (3/2014-1/2015); Health Counsel, House E&C Committee, Pallone (1/2015-3/2017), Sr. Health Counsel, Sen. Finance Cmte, Wyden (3/2017-2/2021);Dir. OL, Dep. Chief of Staff, CMS

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Value of prescription drugs and patient access Issues related to Medicare Parts B & D, MFN Promoting U.S. competitiveness while ensuring U.S. leadership role in developing medicines Health care workforce Clinical Trial Modernization Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.